Gregory M. Glenn, President, R&D at NOVAVAX INC (NVAX), sold 973 shares at $207.01 ($202K) on 2021-09-30, disclosed to the SEC on 2021-10-01.
Open-market sale of $202k NVAX by President, R&D. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $202.84 | 51 | $10K | 5.1% |
| 2 | $203.94 | 55 | $11K | 5.6% |
| 3 | $205.01 | 16 | $3K | 1.6% |
| 4 | $207.01 | 280 | $58K | 28.8% |
| 5 | $207.01 | 280 | $58K | 28.8% |
| 6 | $207.99 | 117 |
| $24K |
| 12.1% |
| 7 | $209.27 | 118 | $25K | 12.2% |
| 8 | $210.16 | 40 | $8K | 4.2% |
| 9 | $211.39 | 16 | $3K | 1.7% |
| Total | $207.18 avg | 973 | $202K | 100% |
| Filing → |
| NVAX | SELL | 2021-12-09 | $1.6M | — | Filing → |
| NVAX | SELL | 2021-12-02 | $3.2M | — | Filing → |
| NVAX | SELL | 2021-11-30 | $719K | — | Filing → |